Page 1457 - Williams Hematology ( PDFDrive )

1432 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1433

1028. Klepin H, Balducci L: Acute myelogenous leukemia in older adults, Oncologist 13:222, 1053. Herzig RH: High-dose ara-C in older adults with acute leukemia. Leukemia 10(Suppl 1):
2009. S10, 1996.
1029. Klepin HD, Geiger AM, Tooze JA, et al: Geriatric assessment predicts survival for 1054. Letendre L, Noel P, Litzow MR, et al: Treatment of acute myelogenous leukemia in the
older adults receiving induction chemotherapy for acute myelogenous leukemia. older patient with attenuated high-dose ara-C. Am J Clin Oncol 21:142, 1998.
Blood 121:4287, 2013. 1055. Schiller G, Lee M: Long-term outcome of high-dose cytarabine-based consolidation
1030. Baz R, Rodriguez C, Fu AZ, et al: Impact of remission induction chemotherapy on chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma
survival in older adults with acute myeloid leukemia. Cancer 110:1752, 2007. 25:111, 1997.
1031. Juliusson G, Antunovic P, Derolf A, et al: Age and acute myeloid leukemia: Real world 1056. Löwenberg B: Post-remission treatment of acute myelogenous leukemia. N Engl J Med
data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. 332:260, 1995.
Blood 113:4179, 2009. 1057. Gardin C, Turlure P, Fagot T, et al: Postremission treatment of elderly patients with
1032. Deschler B, de Witte T, Mertelsmann R, Lübbert M: Treatment decision-making for acute myeloid leukemia in first complete remission after intensive induction chemo-
older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: therapy: Results of the multicenter randomized Acute Leukemia French Association
Problems and approaches. Haematologica 91:1513, 2006. (ALFA) 9803 trial. Blood 109:5129, 2007.
1033. Kantarjian H, Ravandi F, O’Brien S, et al: Intensive chemotherapy does not ben- 1058. DeLima M, Ghaddar H, Pierce S, Estey E: Treatment of newly-diagnosed acute myel-
efit most older patients (age 70 year or older) with acute myeloid leukemia. Blood ogenous leukaemia in patients aged 80 years and above. Br J Haematol 93:89, 1996.
116:4422, 2010. 1059. Burnett AK, Mohite U: Treatment of older patients with acute myeloid leukemia—
1034. Malfusion J-V, Etienne A, Turlure P, et al: Risk factors and decision criteria for inten- New agents. Semin Hematol 43:96, 2006.
sive chemotherapy in older patients with acute myeloid leukemia. Haematologica 1060. Estey EH: Older adults: Should the paradigm shift from standard therapy? Best Pract
93:1806, 2008. Res Clin Haematol 21:61, 2008.
1035. Kalaycio M, Pohlman B, Elson P, et al: Chemotherapy for acute myelogenous leukemia 1061. Etienne A, Esterni B, Charbonnier A, et al: Comorbidity is an independent predictor
in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony- of complete remission in elderly patients receiving induction chemotherapy for acute
stimulating factor. Am J Clin Oncol 24:58, 2001. myeloid leukemia. Cancer 109:1376, 2007.
1036. Bennett CL, Hynes D, Godwin J, et al: Economic analysis of granulocyte colony stimulat- 1062. Gupta V, Xu W, Keng C, et al: The outcome of intensive induction therapy in patients
ing factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): > or = 70 years with acute myeloid leukemia. Leukemia 21:1321, 2007.
Estimates from a Southwest Oncology Group clinical trial. Cancer Invest 19:603, 2001. 1063. Estey EH: General approach to, and perspectives on clinical research in, older patients
1037. Löwenberg B, Suciu S, Archimbaud E, et al: Mitoxantrone versus daunorubicin in with newly diagnosed acute myeloid leukemia. Semin Hematol 43:89, 2006.
induction-consolidation chemotherapy—The value of low-dose cytarabine for 1064. Johnson PR, Yin JA: Prognostic factors in elderly patients with acute myeloid leu-
maintenance of remission, and an assessment of prognostic factors in acute myeloid kaemia. Leuk Lymphoma 16:51, 1994.
leukemia in the elderly: Final report. European Organization for the Research and 1065. Oberg G, Killander A, Björeman M, et al: Long-term follow-up of patients > or = 60 yr
Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon old with acute myeloid leukaemia. Eur J Haematol 68:376, 2002.
Group. J Clin Oncol 16:872, 1998. 1066. Stone RM: The difficult problem of acute myeloid leukemia in the older adult. CA
1038. Harousseau JL, Rigal-Huguet F, Hurteloup P, et al: Treatment of acute myeloid leukemia Cancer J Clin 52:363, 2002.
in elderly patients with oral idarubicin as a single agent. Eur J Haematol 42:182, 1989. 1067. Alibhai SM, Leach M, Kermalli H, et al: The impact of acute myeloid leukemia and
1039. Anderson JE, Kopecky KJ, Willman CL, et al: Outcome after induction chemotherapy its treatment on quality of life and functional status in older adults. Crit Rev Oncol
for older patients with acute myeloid leukemia is not improved with mitoxantrone Hematol 64:19, 2007.
and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology 1068. Büchner T, Berdel WE, Wörmann B, et al: Treatment of older patients with AML. Crit
Group study. Blood 100:3869, 2002. Rev Oncol Hematol 56:247, 2005.
1040. Hartman F, Jacobs G, Gotto H, et al: Cytosine arabinoside, idarubicin and divided 1069. Surveillance, Epidemiology, and End Results (SEER): Myeloid leukemia: 5-Year rel-
dose etoposide for the treatment of acute myeloid leukemia in elderly patients. Leuk ative and period survival by race, sex, diagnosis year and age, 1975-2011. Available
Lymphoma 42:347, 2001. at: http://seer.cancer.gov/csr/1975_2011/browse_csr.php?sectionSEL=13&pageSE-
1041. Kanemura N, Tsurumi H, Kasahara S, et al: Continuous drip infusion of low dose L=sect_13_table.16.html
cytarabine and etoposide with granulocyte colony-stimulating factor for elderly 1070. Prebet T, Boissel N, Reutenauer S, et al: Acute myeloid leukemia with translocation
patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematol (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A
Oncol 26:33, 2008. collaborative study of the French CBF-AML intergroup. J Clin Oncol 27:4747, 2009.
1042. Brandwein JM, Yang L, Schimmer AD, et al: A phase II study of temozolomide ther- 1071. Perrot A, Luquet I, Pigneux A, et al: Dismal prognostic value of monosomal karyotype
apy for poor-risk patients aged > or = 60 years with acute myeloid leukemia: Low in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients
levels of MGMT predict for response. Leukemia 21:821, 2007. with unfavorable cytogenetic abnormalities. Blood 118:679, 2011.
1043. Faderl S, Ravandi F, Huang X, et al: A randomized study of clofarabine versus clo- 1072. Renosos EE, Shepard FA, Messner HA, et al: Acute leukemia during pregnancy: The
farabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and Toronto Leukemia Study Group Experience with long-term follow-up of children
older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood exposed in utero to chemotherapeutic agents. J Clin Oncol 5:1098, 1987.
112:1638, 2008. 1073. Caligiuri MA, Mayer RJ: Pregnancy and leukemia. Semin Oncol 16:388, 1989.
1044. Burnett AK, Russell NH, Kell J, et al: European development of clofarabine as treat- 1074. Chang A, Patel S: Treatment of acute myeloid leukemia during pregnancy: A system-
ment for older patients with acute myeloid leukemia considered unsuitable for inten- atic review of the literature. Ann Pharmacother 49:48, 2015.
sive chemotherapy. J Clin Oncol 28:2389, 2010. 1075. Chelghoum Y, Vey N, Raffoux E, et al: Acute leukemia during pregnancy: A report on
1045. Kantarjian HM, Erba HP, Claxton D, et al: Phase II study of clofarabine monotherapy 37 patients and a review of the literature. Cancer 104:110, 2005.
in previously untreated older adults with acute myeloid leukemia and unfavorable 1076. Salah AJ, Alhejazi A, Ahmed SO, et al: Leukemia during pregnancy: Long term follow
prognostic factors. J Clin Oncol 28:549, 2009. up of 32 cases form a single institution. Hematol Oncol Stem Cell Ther 7:63, 2014.
1046. Ossenkoppele GJ, Stussi G, Maertens J, et al: Addition of bevacizumab to chemo- 1077. Aviles A, Neri N: Hematological malignancies and pregnancy: A final report of
therapy in acute myeloid leukemia at older age: A randomized phase 2 trial of the 84 children who received chemotherapy in utero. Clin Lymphoma 2:173, 2001.
Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the 1078. Greenlund LJ, Letendre L, Tefferi A: Acute leukemia during pregnancy: A single insti-
Swiss Group for Cancer Research (SAKK). Blood 120:4706, 2012. tutional experience with 17 cases. Leuk Lymphoma 41:571, 2001.
1047. Serve H, Krug U, Wagner R, et al: Sorafenib in combination with intensive chemo- 1079. Shapira T, Pereg D, Lishner M: How I treat acute and chronic leukemia in pregnancy.
therapy in elderly patients with acute myeloid leukemia: Results from a randomized, Blood Rev 22:247, 2008.
placebo-controlled trial. J Clin Oncol 31:3110, 2013. 1080. Osada S, Horibe K, Oiwa K, et al: A case of infantile acute monocytic leukemia caused
1048. Burnett AK, Hills RK, Hunter AE, et al: The addition of gemtuzumab ozogamicin to by vertical transmission of the mother’s leukemic cells. Cancer 65:1146, 1990.
low-dose Ara-C improves remission rate but does not significantly prolong survival in 1081. Lipovsky MM, Biesma DH, Christiaens GC, Petersen EJ: Successful treatment of acute
older patients with acute myeloid leukaemia: Results from the LFR AML14 and NCRI promyelocytic leukaemia with all-trans retinoic acid during late pregnancy. Br J Hae-
AML16 pick-a-winner comparison. Leukemia 27:75, 2013. matol 94:669, 1996.
1049. Amadori S, Suciu S, Stasi R, et al: Sequential combination of gemtuzumab ozogamicin 1082. Valappil S, Kurkar M, Howell R, et al: Outcome of pregnancy in women treated with
and standard chemotherapy in older patients with newly diagnosed acute myeloid all-trans retinoic acid; a case report and review of literature. Hematology 12:415, 2007.
leukemia; results of a randomized phase III trial by the EORTC and GIMEMA con- 1083. Gregory J, Arceci R: Acute myeloid leukemia in children: A review of risk factors and
sortium (AML-17). J Clin Oncol 31:4424, 2013. recent trials. Cancer Invest 20:1027, 2002.
1050. Schiller GJ: Postremission therapy of acute myeloid leukemia in older adults. Leuke- 1084. Clark JJ, Smith FO, Arceci RJ: Update in childhood myeloid leukemia: Recent devel-
mia 10(Suppl 1):S18, 1996. opments in the molecular basis of disease and novel therapies. Curr Opin Hematol
1051. Kiss TL, Sabry W, Lazarus HM, Lipton JH: Blood and marrow transplantation in 10:31, 2002.
elderly acute myeloid leukaemia patients—Older certainly is not better. Bone Marrow 1085. Arceci RJ: Progress and controversies in the treatment of pediatric acute myelogenous
Transplant 40:405, 2007. leukemia. Curr Opin Hematol 9:353, 2002.
1052. McClune BL, Weisdorf DJ, Pedersen TI, et al: Effect of age on outcome of reduced- 1086. Webb DKH, Harrison G, Stevens RF, et al: Relationships between age at diagnosis,
intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia clinical features, and outcome of therapy in children in the Medical Research Council
in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878, 2010. AML 10 and 12 trials for acute myeloid leukemia. Blood 98:1714, 2001.

Kaushansky_chapter 88_p1373-1436.indd 1432 9/21/15 11:02 AM